BACKGROUND: Gastrointestinal (GI) dysmotility may present secondary to inflammatory bowel disease. The main aim of this study was to investigate GI motility in ulcerative colitis (UC) patients during severe disease activity. METHODS: Twenty patients with severe UC were studied with a novel telemetric capsule system (3D-Transit) designed for minimally invasive, ambulatory assessment of total and regional GI transit times. Ten patients were available for follow-up during remission. Data were compared to those of 20 healthy subjects (HS). KEY RESULTS: Total GI transit time was significantly longer in patients with severe UC (median 44.5 h [range 9.9-102.7 h]) than in HS (median 27.6 h [range 9.6-56.4 h]) (p = 0.032). Additionally, during severe UC, transit time was prolonged through the proximal colon (p = 0.003) and there were strong trends toward longer than normal small intestinal transit time (HS: median 4.9 h [range 3.4-8.3 h] vs severe UC patients: median 5.9 h [range 3.9-11.9 h]; p = 0.053) and colorectal transit times (HS: median 18.2 h [range 1.5-43.7] vs severe UC patients: median 34.9 h [range 0.4-90.9 h]; p = 0.056). Our data further indicate that total GI and colorectal transit times may be prolonged in UC during early remission. CONCLUSIONS & INFERENCES: Total GI transit times are significantly prolonged during severe UC.
BACKGROUND: Gastrointestinal (GI) dysmotility may present secondary to inflammatory bowel disease. The main aim of this study was to investigate GI motility in ulcerative colitis (UC) patients during severe disease activity. METHODS: Twenty patients with severe UC were studied with a novel telemetric capsule system (3D-Transit) designed for minimally invasive, ambulatory assessment of total and regional GI transit times. Ten patients were available for follow-up during remission. Data were compared to those of 20 healthy subjects (HS). KEY RESULTS: Total GI transit time was significantly longer in patients with severe UC (median 44.5 h [range 9.9-102.7 h]) than in HS (median 27.6 h [range 9.6-56.4 h]) (p = 0.032). Additionally, during severe UC, transit time was prolonged through the proximal colon (p = 0.003) and there were strong trends toward longer than normal small intestinal transit time (HS: median 4.9 h [range 3.4-8.3 h] vs severe UC patients: median 5.9 h [range 3.9-11.9 h]; p = 0.053) and colorectal transit times (HS: median 18.2 h [range 1.5-43.7] vs severe UC patients: median 34.9 h [range 0.4-90.9 h]; p = 0.056). Our data further indicate that total GI and colorectal transit times may be prolonged in UC during early remission. CONCLUSIONS & INFERENCES: Total GI transit times are significantly prolonged during severe UC.
Authors: G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi Journal: Tech Coloproctol Date: 2020-02-15 Impact factor: 3.781
Authors: Lauren Sahakian; Rhiannon T Filippone; Rhian Stavely; Ainsley M Robinson; Xu Sean Yan; Raquel Abalo; Rajaraman Eri; Joel C Bornstein; Mark R Kelley; Kulmira Nurgali Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Glynn Martin; Sofia Kolida; Julian R Marchesi; Elizabeth Want; James E Sidaway; Jonathan R Swann Journal: Front Microbiol Date: 2018-06-05 Impact factor: 5.640
Authors: Maura Corsetti; Marcello Costa; Gabrio Bassotti; Adil E Bharucha; Osvaldo Borrelli; Phil Dinning; Carlo Di Lorenzo; Jan D Huizinga; Marcel Jimenez; Satish Rao; Robin Spiller; Nick J Spencer; Roger Lentle; Jasper Pannemans; Alexander Thys; Marc Benninga; Jan Tack Journal: Nat Rev Gastroenterol Hepatol Date: 2019-07-11 Impact factor: 46.802
Authors: Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth Journal: Pharmaceutics Date: 2022-01-26 Impact factor: 6.321
Authors: Arnab Mukherjee; Shinichi Tsuchiwata; Cheng Chang; Timothy Nicholas; Chinyu Su; Vu H Le; Joseph Kushner; Nicole Kulisek Journal: Clin Pharmacol Drug Dev Date: 2022-05-13